Literature DB >> 21990165

Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.

Maxime P Vallée1, Tiana C Francy, Megan K Judkins, Davit Babikyan, Fabienne Lesueur, Amanda Gammon, David E Goldgar, Fergus J Couch, Sean V Tavtigian.   

Abstract

Unclassified sequence variants (UVs) arising from clinical mutation screening of cancer susceptibility genes present a frustrating issue to clinical genetics services and the patients that they serve. We created an open-access database holding missense substitutions from the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2. The main inclusion criterion is that each variant should have been assessed in a published work that used the Bayesian integrated evaluation of unclassified BRCA gene variants. Transfer of data on these substitutions from the original publications to our database afforded an opportunity to analyze the missense substitutions under a single model and to remove inconsistencies that arose during the evolution of the integrated evaluation over the last decade. This analysis also afforded the opportunity to reclassify these missense substitutions according to the recently published IARC 5-Class system. From an initial set of 248 missense substitutions, 31 were set aside due to nonnegligible probability to interfere with splicing. Of the remaining substitutions, 28 fell into one of the two pathogenic classes (IARC Class 4 or 5), 174 fell into one of the two nonpathogenic classes (IARC Class 1 or 2), and 15 remain in IARC Class 3, "Uncertain." The database is available at http://brca.iarc.fr/LOVD.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21990165      PMCID: PMC3478957          DOI: 10.1002/humu.21629

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  29 in total

1.  Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.

Authors:  V Abkevich; A Zharkikh; A M Deffenbaugh; D Frank; Y Chen; D Shattuck; M H Skolnick; A Gutin; S V Tavtigian
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

2.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.

Authors:  David E Goldgar; Douglas F Easton; Amie M Deffenbaugh; Alvaro N A Monteiro; Sean V Tavtigian; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2004-08-02       Impact factor: 11.025

3.  Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.

Authors:  Thaddeus Judkins; Brant C Hendrickson; Amie M Deffenbaugh; Kristilyn Eliason; Benoît Leclair; Michael J Norton; Brian E Ward; Dmitri Pruss; Thomas Scholl
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.

Authors:  Kangjian Wu; Shannon R Hinson; Akihiro Ohashi; Daniel Farrugia; Patricia Wendt; Sean V Tavtigian; Amie Deffenbaugh; David Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

5.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

Authors:  Georgia Chenevix-Trench; Sue Healey; Sunil Lakhani; Paul Waring; Margaret Cummings; Ross Brinkworth; Amie M Deffenbaugh; Lynn Anne Burbidge; Dmitry Pruss; Thad Judkins; Tom Scholl; Anna Bekessy; Anna Marsh; Paul Lovelock; Ming Wong; Andrea Tesoriero; Helene Renard; Melissa Southey; John L Hopper; Koulis Yannoukakos; Melissa Brown; Douglas Easton; Sean V Tavtigian; David Goldgar; Amanda B Spurdle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

6.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

7.  Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.

Authors:  P K Lovelock; S Healey; W Au; E Y M Sum; A Tesoriero; E M Wong; S Hinson; R Brinkworth; A Bekessy; O Diez; L Izatt; E Solomon; M Jenkins; H Renard; J Hopper; P Waring; S V Tavtigian; D Goldgar; G J Lindeman; J E Visvader; F J Couch; B R Henderson; M Southey; G Chenevix-Trench; A B Spurdle; M A Brown
Journal:  J Med Genet       Date:  2005-05-27       Impact factor: 6.318

Review 8.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

Authors:  B Evers; J Jonkers
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

9.  LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach.

Authors:  Ivo F A C Fokkema; Johan T den Dunnen; Peter E M Taschner
Journal:  Hum Mutat       Date:  2005-08       Impact factor: 4.878

10.  Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.

Authors:  John E Wagner; Jakub Tolar; Orna Levran; Thomas Scholl; Amie Deffenbaugh; Jaya Satagopan; Leah Ben-Porat; Katherine Mah; Sat Dev Batish; David I Kutler; Margaret L MacMillan; Helmut Hanenberg; Arleen D Auerbach
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

View more
  40 in total

1.  Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory.

Authors:  William Gradishar; KariAnne Johnson; Krystal Brown; Erin Mundt; Susan Manley
Journal:  Oncologist       Date:  2017-04-13

2.  Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.

Authors:  Tehillah S Menes; Mary Beth Terry; David Goldgar; Irene L Andrulis; Julia A Knight; Esther M John; Yuyan Liao; Melissa Southey; Alexander Miron; Wendy Chung; Saundra S Buys
Journal:  Breast Cancer Res Treat       Date:  2015-05-15       Impact factor: 4.872

3.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

4.  Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.

Authors:  David J Hermel; Wendy C McKinnon; Marie E Wood; Marc S Greenblatt
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

5.  Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.

Authors:  William I Towler; Jie Zhang; Derek J R Ransburgh; Amanda E Toland; Chikashi Ishioka; Natsuko Chiba; Jeffrey D Parvin
Journal:  Hum Mutat       Date:  2012-12-12       Impact factor: 4.878

Review 6.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.

Authors:  Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

7.  Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.

Authors:  Akihiro Ohmoto; Chigusa Morizane; Emi Kubo; Erina Takai; Hiroko Hosoi; Yasunari Sakamoto; Shunsuke Kondo; Hideki Ueno; Kazuaki Shimada; Shinichi Yachida; Takuji Okusaka
Journal:  J Gastroenterol       Date:  2018-04-17       Impact factor: 7.527

8.  Predicting the Pathogenic Potential of BRCA1 and BRCA2 Gene Variants Identified in Clinical Genetic Testing.

Authors:  Clare Brookes; Stella Lai; Elaine Doherty; Donald R Love
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

Review 9.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

10.  BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.

Authors:  Amanda B Spurdle; Phillip J Whiley; Bryony Thompson; Bingjian Feng; Sue Healey; Melissa A Brown; Christopher Pettigrew; Christi J Van Asperen; Margreet G E M Ausems; Anna A Kattentidt-Mouravieva; Ans M W van den Ouweland; Annika Lindblom; Maritta H Pigg; Rita K Schmutzler; Christoph Engel; Alfons Meindl; Sandrine Caputo; Olga M Sinilnikova; Rosette Lidereau; Fergus J Couch; Lucia Guidugli; Thomas van Overeem Hansen; Mads Thomassen; Diana M Eccles; Kathy Tucker; Javier Benitez; Susan M Domchek; Amanda E Toland; Elizabeth J Van Rensburg; Barbara Wappenschmidt; Åke Borg; Maaike P G Vreeswijk; David E Goldgar
Journal:  J Med Genet       Date:  2012-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.